Veritas In Silico (TSE:130A) Other Stockholders Equity: 円0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:130A Veritas In Silico Inc TSE:130A
13 GF Score
Price 円406.00
! 4 Warning Signs
View Full Analysis

What is Veritas In Silico Other Stockholders Equity?

Veritas In Silico TSE:130A 13 Other Stockholders Equity is 円0.00 Mil as of Dec. 2025. GuruFocus rates TSE:130A with a GF Score™ of 13/100. The stock has 4 warning signs investors should review.

Veritas In Silico's Other Stockholders Equity for the quarter that ended in Dec. 2025 was 円0.00 Mil.

Veritas In Silico's quarterly Other Stockholders Equity stayed the same from Jun. 2025 (円0.00 Mil) to Sep. 2025 (円0.00 Mil) and stayed the same from Sep. 2025 (円0.00 Mil) to Dec. 2025 (円0.00 Mil).

Veritas In Silico's annual Other Stockholders Equity stayed the same from Dec. 2023 (円0.00 Mil) to Dec. 2024 (円0.00 Mil) but then increased from Dec. 2024 (円0.00 Mil) to Dec. 2025 (円0.00 Mil).

Veritas In Silico Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Veritas In Silico's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veritas In Silico Other Stockholders Equity Chart

Veritas In Silico Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
-0.00 0.00 0.00 0.00 0.00

Veritas In Silico Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
TSE:130A
13GF Score
Veritas In Silico Inc TSE:130A
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veritas In Silico Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of 円0.00 Mil mean?
Veritas In Silico (TSE:130A) has a Other Stockholders Equity of 円0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Veritas In Silico and its competitors.
Is Veritas In Silico's Other Stockholders Equity too high?
Veritas In Silico's current Other Stockholders Equity is 円0.00 Mil. Overall, Veritas In Silico has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's Other Stockholders Equity compare to VRTX and REGN?
Veritas In Silico's Other Stockholders Equity of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Veritas In Silico and its competitors. Veritas In Silico's current Other Stockholders Equity is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Veritas In Silico (TSE:130A) has a current Other Stockholders Equity of 円0.00 Mil. The current Other Stockholders Equity is 円0.00 Mil. Veritas In Silico's overall GF Score™ is 13/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current Other Stockholders Equity is 円0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veritas In Silico Business Description

Address 1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
13GF Score

Get the complete analysis for TSE:130A

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円406.00
Price